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Background: We evaluated the clinical outcome of low grade Ta bladder cancer followed-up for a long period
using the 2004 WHO grading system.
Methods: We retrospectively reviewed 190 patients with primary, low grade Ta bladder cancer. We defined
worsening progression (WP) as confirmed high grade Ta, all T1 or Tis/concomitant CIS of bladder recurrence, upper
urinary tract recurrence (UTR), or progression to equal to or more than T2. The associations between
clinicopathological factors and tumor recurrence as well as WP pattern were analyzed. We also evaluated the late
recurrence of 76 patients who were tumor-free for more than 5 years.
Results: Tumor recurrence and WP occurred in 82 (43.2%) and 21 (11.1%) patients during follow-up (median
follow-up: 101.5 months), respectively. WP to high grade Ta, all T1 or Tis/concomitant CIS was seen in 17 patients,
and UTR and progression to equal to or more than T2 were seen in 2 and 2 patients, respectively. Multivariate
analyses demonstrated that multiple tumor (p < 0.001, HR: 2.97) and absence of intravesical instillation (IVI)
(p < 0.001, HR: 2.88) were significant risk factors for tumor recurrence while multiple tumor was the only risk factor
for WP (p = 0.001, HR: 5.26). After a 5-year tumor-free period, 9 patients experienced late recurrence in years 5 and
10 and were diagnosed at a follow-up cystoscopy, however, only 2 patients recurred beyond 10 years and were
found by gross hematuria. There were no significant risk factors of late recurrence.
Conclusions: Multiple tumor was a risk factor for both tumor recurrence and WP while IVI did not affect the
occurrence of WP. Our results suggest that routine follow-up of patients with low grade Ta bladder cancer is
needed up to 10 years from the initial diagnosis.
Keywords: Bladder cancer, Intravesical instillation, Recurrence, ProgressionBackground
Approximately 50 % of newly diagnosed cases of bladder
cancer are low grade, noninvasive and papillary tumors
[1]. The standard treatment for non-muscle invasive
bladder cancer (NMIBC) is transurethral resection of
the bladder tumor (TUR-BT) with or without adjuvant
intravesical instillation (IVI) of chemotherapy or Bacillus* Correspondence: eiji-k@kb3.so-net.ne.jp
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reproduction in any medium, provided the orCalmette-Guerin (BCG) therapy [2]. The most important
problems associated with NMIBC are that they have
high rates of recurrence and risk of progression. Ap-
proximately 50% to 70% of NMIBC have a recurrence
within 5 years, and 5% to 20% progress to invasive tu-
mors [3]. To the best of our knowledge, there have been
no reports with longer follow-up data focusing on the ef-
fects of IVI on tumor recurrence and progression in pa-
tients with low grade Ta tumors based on the 2004
WHO classification [4,5]. Also, there are few published
studies in which a large number of patients wereral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Only two papers provide information on the risk of re-
currence and progression after a long tumor-free period
[6,7]. Although some long follow-up studies also showed
most tumors recurred or progressed within 5 years, re-
cent data support the need for long term follow-up for
more than 10–15 years in such patients even after an
initial response to BCG therapy and a recurrence-free
period for more than 5 years [6].
In this study, we analyzed the clinical outcome of ini-
tially diagnosed low grade Ta tumors after re-assessing
all pathological specimens according to the 2004 WHO
classification, with a special focus on tumor recurrence
and worsening progression (WP) pattern and discuss the
need for longer follow-up.
Methods
We reviewed the medical records of 242 patients (male:
199, female: 43) who underwent TUR-BT with complete
tumor resection for the past 30 years at Keio University
Hospital for an initially diagnosed TaG1-2 tumor. We
excluded 44 patients who had already undergone TUR-
BT at another hospital or who had a history of upper
tract urothelial cancer. After re-evaluation of all patho-
logical specimens by a dedicated uro-pathologist, with a
special focus on the 2004 WHO grading system, 8 pa-
tients with G2 tumors were re-classified as high grade.
The remaining 190 NMIBC patients (male: 156, female:
34) who were initially diagnosed with a tumor that was
low grade Ta were included in the current analysis. All
of the tumors were histologically confirmed as urothelial
carcinoma.
These patients were followed by urine cytology and
cystoscopy at 3-month intervals during the initial year,
every 6 months for the next 5 years, and then yearly
thereafter. Intravenous urography, ultrasonography,
and/or CT scanning were used to evaluate distant me-
tastasis and upper urinary tract recurrence (UTR) every
1 or 2 years for 5 years. Recurrence was defined as the
occurrence of a new tumor in the bladder. Worsening
progression (WP) was defined as confirmed (1) high
grade Ta, all T1, or Tis/concomitant CIS of bladder re-
currence, (2) UTR, or (3) progression to equal to or
more than T2.
The use of adjuvant therapies including intravesical
BCG or mitomycin (MMC) instillation depended pri-
marily on the discretion of the attending physician. In
the overall patient population, BCG and MMC therapies
were performed in 71 patients (37.4%) and 12 patients
(6.3%), respectively. This study was approved by Keio
university hospitals ethical committee. We obtained the
patient’s informed consent including their approval for
potential use of their anonymized medical data from our
data base for research and audit purposes.The following were analyzed for each individual pa-
tient: age, gender, multiplicity and smoking status.
Smoking status was classified as 1) nonsmokers; those
who had never smoked during their lifetime, 2) ex-
smokers; those who had quit smoking before the diag-
nosis and 3) current smokers; those who still smoked
regularly at the initial TUR-BT. Recurrence-free sur-
vival rate curves were constructed using the Kaplan-
Meier method, and were compared using the log-rank
test. Differences among groups were regarded as signifi-
cant when p < 0.05. Univariate and multivariate analyses
of data were performed using the Cox proportional
hazards model with stepwise forward selection. These
analyses were performed with a statistical software
package (SPSS, version 19.0).
Results
Tumor recurrence and worsening progression rate in
entire patient population
The mean age of the patients was 62.9 years (range, 22–
89) and the median follow-up interval was 101.5 months
(range, 11.1 to 298.2). Solitary/multiple tumors were
seen in 114/76 patients, respectively. Tumor recurrence
occurred in 82 patients (43.2%). Most patients who had
tumor recurrence could be diagnosed by the routine
follow-up cystoscopic examination except for 3 patients
(3.7%) who were detected due to gross hematuria. When
we divided the patients into two groups, those with or
without tumor recurrence, there were no significant dif-
ferences in age, gender, IVI or smoking status between
the two groups (Table 1). The recurrence rate in mul-
tiple tumors (53.9%) was significantly higher than that in
solitary tumors (36.0%). Univariate and multivariate ana-
lyses demonstrated that multiple tumor and absence of
IVI were significant risk factors for tumor recurrence
(Table 2). Kaplan-Meier curves demonstrated that the 5-
year recurrence free survival rate for solitary tumors
(68.0%) was significantly higher than that for multiple
tumors (45.9%, p = 0.001) (Figure 1A), and also higher
for patients receiving intravesical instillation (71.3% vs.
50.3% without IVI, p = 0.007) (Figure 1B).
Overall WP occurred in 21 patients (11.1%) and the
average time to WP was 82.4 months (range, 5.6-298.2).
WP to high grade Ta, all T1, or Tis/concomitant CIS of
bladder recurrence was seen in 4, 8 and 5 patients, re-
spectively, UTR was seen in 2 patients (1.1%), and pro-
gression to equal to or more than T2 was observed in 2
patients (1.1%). Also, there were various types of timing
and intervals for WP. Twenty of 21 patients (95.2%) ex-
perienced WP until the 2nd recurrence and 12 patients
(57.1%) experienced WP on the 1st recurrence. All 8 pa-
tients who experienced WP on the 2nd recurrence had a
low grade Ta type tumor on the 1st recurrence, and the
average time between the 1st and 2nd recurrence was
Table 1 Clinical characteristics of all 190 patients
Total Recurrence (+) Recurrence (−) p value WP (+) WP (−) p value
N 190 82 108 21 169
Age (y) Mean Range 62.9 63.0 62.9 64.9 62.7
22-89 26-83 22-89 47-83 22-89
≤70 128 56 72 NS 14 114 NS
>70 62 26 36 7 55
Gender Male 156 72 84 NS 19 137 NS
Female 34 10 24 2 32
Multiplicity Solitary 114 41 73 0.017 7 107 0.016
Multiple 76 41 35 14 62
IVI Yes 83 29 54 NS 11 72 NS
No 107 53 54 10 97
Smoking None 100 40 60 NS 10 90 NS
Current 56 29 27 9 47
Ex-smoker 27 10 17 2 25
Unknown 7 3 4 0 7
IVI intravesical instillation, WP worsening progression, NS non-significant.
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enced minor recurrences three times and WP occurred
on the 4th recurrence. The three recurrences were all
low grade Ta, and in the end WP to high grade T1 oc-
curred although intravesical chemotherapy and BCG in-
stillations were performed after every TUR-BT.
When we divided the patients into two groups, those
with or without WP, there were no significant differ-
ences in age, gender, IVI or smoking status between the
two groups (Table 1). WP occurred more often in the
multiple tumor group (18.4%) than in the solitary tumor
group (6.1%) and the difference was significant (p =
0.016). Univariate and multivariate analyses demon-
strated that multiple tumor was the only significant risk
factor for WP (Table 2). Kaplan-Meier curve demon-
strated that the 5-year WP free survival rate for solitary
tumors (97.2%) was significantly higher than that for
multiple tumors (85.5%, p = 0.003) (Figure 2).Table 2 Univariate and multivariate analyses for tumor recurr
Recurrence
Univariate Mu
p value p value
Age (≤70 vs. >70) 0.465
Gender (male vs. female) 0.152
Multiplicity (solitary vs. multiple) 0.001 <0.001
Treatment (IVI vs. observation) 0.007 <0.001
Smoking (nonsmoker vs. smoker) 0.501
IVI intravesical instillation, WP worsening progression, smoker: current smoker + ex-sLate recurrence beyond 5-year tumor-free period
We next focused on patients who were tumor-free for
more than 5 years from initial TUR-BT to first tumor re-
currence and WP, called “late recurrence” and “late
WP”. We identified 76 patients in this category, among
whom adjuvant IVI had been performed in 40 (52.6%)
patients (Table 3). The mean age of the patients was
61.1 years (range, 22–84), and solitary/multiple tumors
were seen in 53/23 patients, respectively. Eleven patients
(14.5%) experienced late recurrence, and of them, 5 pa-
tients (6.6%) had late WP (Table 4). There were no sig-
nificant differences in age, gender, multiplicity, smoking
status or adjuvant IVI performed in patients with or
without late recurrence, and there were no significant
risk factors of late recurrence. The average time to late
recurrence and late WP was 103.5 and 104.5 months, re-
spectively. Nine of 11 patients whose cancer recurred in
years 5 and 10 in our study were diagnosed at a follow-ence and WP in overall patient population
WP
ltivariate Univariate Multivariate
HR p value p value HR
0.444
0.412




Figure 1 Recurrence-free survival rates (A) by tumor multiplicity, (B) by presense of adjuvant intravesical instillation.
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who were tumor-free beyond 10 years was found by
gross hematuria. WP to high grade Ta, low grade T1,
Tis, UTR, and high grade T3 were observed in one
case in each. Also, 4 patients experienced WP on the
first late recurrence while only one patient did on the
2nd recurrence.
Discussion
We reviewed 190 patients with primary, low grade Ta
NMIBC patients and evaluated whether patient-related
factors (age, gender, multiplicity, smoking status and ad-
juvant treatment) were associated with tumor recurrence
and WP. Multivariate analysis demonstrated that multi-
plicity was a risk factor for both tumor recurrence and
WP, and that IVI did not affect the occurrence of WP.
While none of the patients died of bladder cancer duringfollow-up, late recurrence and late WP occurred in 11
and 5 patients, respectively.
Zieger et al. presented the natural history of 212 pa-
tients initially diagnosed with TaG1-2 tumors for up to
20 years. Only 14 patients received intravesical instilla-
tion in their study. Ten of the 212 (4.7%) developed into
TaG3 or CIS, 18 (8.5%) developed into T1, and 23
(10.8%) showed muscle invasion or distant metastases
8]. According to our definition of WP, WP was seen in
24.1% in their study, which was relatively high com-
pared to our study. Similarly, Prout et al. followed 178
patients with TaG1 bladder tumors for up to 10 years.
They reported that a change in grade or stage progres-
sion occurred in 13 (7.3%) patients, while only 14 pa-
tients (7.9%) received intravesical chemotherapy [9].
Akagashi et al. reported no patients initially diagnosed
with TaG1-2 tumors progressed to muscle invasive
Figure 2 WP-free survival rates by tumor multiplicity.
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or T1. One reason for this low percentage of progression
was that most of the patients received intravesical
chemotherapy for more than 2 years [10]. From these re-
ports, the recurrence rate of initially diagnosed TaG1-2
bladder cancer was 50-60%, and the WP rate was highly
variable (between 7% and 24%). In our population of ini-
tially diagnosed low grade Ta bladder tumors, the recur-
rence rate and WP rate were 43.2% and 11.1%,
respectively.
We reviewed longer follow-up data for a maximum of
25 years and re-assessed all pathological specimens using
the 2004 WHO classification. Only 8 of 198 (4.0%) of
G1-2 tumors were re-classified as high grade in ourTable 3 Clinical characteristics of 76 patients with a tumor-fre
Total Lat
N 76













Unknown 1study. Miyamoto et al. evaluated low grade papillary
urothelial carcinoma after re-classifying all specimens
and reported that 8 of 55 patients (14.5%) were re-
classified as having high grade tumors [11]. Pellucchi
et al. evaluated tumor recurrence and progression with
both the 1973 and 2004 WHO grading systems in pa-
tients with primary low grade Ta NMIBC and concluded
that the 1973 WHO grading system predicted the risk of
recurrence more accurately than the 2004 system and
the 2 classifications showed the same accuracy for pre-
dicting the risk of progression [12]. The 2013 EAU
guideline states that both grading classifications should
be used until the 2004 WHO system is validated by
more prospective trials [13].e period for more than 5 years from initial diagnosis
















Table 4 Clinical data for patients with late recurrence and late WP




Follow up (mo) Status of last
contact
1 57 Male Current M 98.4 S, low, Ta 232.6 Alive, NED
2 58 Male None M 117.8 M, high, Tis 172.1 Alive, cystectomy performed
3 58 Male Ex-smoker M 74.0 S, low, Ta 298.2 Alive, NED
4 59 Female None M 97.4 M, low, Ta 118.2 Alive, UTR, NUx performed
5 60 Male None S 166.6 S, low, Ta 178.4 Alive, NED
6 61 Male None S 73.5 S, low, Ta 273.6 Alive, NED
7 62 Male Current S 73.3 S, high, Ta 244.3 Alive, NED
8 67 Male Unknown S 92.9 M, low, Ta 134.8 Alive, NED
9 68 Male Current S 151.8 M, low, T1 206.4 Alive, NED
10 76 Male None S 115.5 S, low, Ta 176.0 Alive, NED
11 78 Male None S 83.1 M, high, T3 96.8 Dead of intercurrent disease
M multiple, S solitary, WP worsening progression, NED no evidence of disease, UTR upper urinary tract recurrence, NUx nephroureterectomy.
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treated with BCG intravesical therapy who were tumor-
free for more than 5 years (N = 204). Of the 204 pa-
tients, 110 (53.9%) had a G1 or G2 tumor. They stated
that patients with TaG1-2 tumors treated with BCG
have a very good long-term prognosis, but late recur-
rences were observed. Furthermore, as all low grade re-
currences were diagnosed at a follow-up cystoscopy
and office cystoscopy generally is a simple procedure,
they concluded that continuing to follow patients with
TaG1-2 for more than 5 years is encouraging [6]. Our
results support their findings. All patients in our study
who experienced recurrence in years 5 and 10 were di-
agnosed at a follow-up cystoscopy. Meanwhile, recur-
rence in 2 patients who had been tumor-free beyond 10
years was found by gross hematuria. These results sug-
gest that follow-up cystoscopy can be discontinued
around 10 years from the initial diagnosis in patients
with low grade Ta bladder cancer.
Smoking status is a well-known risk factor for poor
outcome in bladder cancer and the strong association
between smoking and primary NMIBC recurrence was
observed in previous studies [14-16]. However, our re-
sults revealed that smoking status is not associated with
bladder recurrence rate, WP rate, or late recurrence rate.
One of the reasons for our negative result is that the
relatively lower percentage of smokers and lower
amount of smoking in Japanese NMIBC populations.
Further studies with a larger population are warranted
in order to evaluate the association between smoking
status and tumor outcome in low grade Ta NMIBC.
The present study has several limitations. First, it was
performed in a retrospective manner with a limited
number of patients, thus unknown sources of bias may
exist in the findings. However, since we re-reviewed allpathological specimens and reclassified them as absolute
low grade tumors, our results represent more reliable
data compared to data obtained before re-evaluation.
Second, in our database, tumor size/volume was not in-
cluded routinely because of the inaccuracy of measure-
ments of tumor size by cystoscopic findings. Finally, we
did not provide all patients with a single immediate
postoperative instillation of chemotherapy within 24 h
or any maintenance intravesical therapies, which may
have improved the results.Conclusions
The tumor recurrence rate and WP rate in patients with
primary, low grade Ta bladder cancer were 43.2 % and
11.1 %, respectively. Multiple tumor was a risk factor for
both tumor recurrence and WP, while IVI did not affect
the occurrence of WP. The late recurrence rate and late
WP rate were 14.5 % and 6.6 %, respectively. Our results
suggest that routine follow-up of patients with low grade
Ta bladder cancer is needed up to 10 years from the ini-
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